Financial Forecast - The company forecasts a net profit of approximately CNY 35 million to CNY 55 million for the year 2025, representing a decline of 60.65% to 74.96% compared to the previous year's net profit of CNY 139.768 million[5]. - The performance forecast is based on preliminary calculations and has not been audited by an accounting firm, emphasizing the need for investors to be cautious and aware of investment risks[8]. Profit Decline Factors - The decrease in net profit is attributed to a lower sales proportion of high-margin hematopoietic series products 1 and 2, while the sales proportion of lower-margin hematopoietic series product 3 increased, leading to a reduction in overall gross profit margin[6]. - The company experienced an increase in management expenses due to higher intermediary service fees and personnel compensation, contributing to the decline in net profit[7]. - The investment income from joint ventures decreased during the reporting period, further impacting the net profit negatively[7].
驱动力(920275) - 2025 Q4 - 年度业绩预告